These compounds have comparable cytotoxicity against breast cancer cells with different genetic backgrounds (p53 wild-type or mutant; ER positive or TNBC), indicating a p53-independent and ER-independent mechanism of action. This evidence concerns the gene ESR1 and breast cancer.